دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Early Implementation of Aldosterone-Targeted Therapy in Patients With Hypertension.
Pitt, Bertram MD; Vaidya, Anand MD, MMSc
doi : 10.1161/CIRCULATIONAHA.123.064318
Volume 147(13) pgs. 991-1052 March 28, 2023
Exercise Volume Versus Intensity and the Progression of Coronary Atherosclerosis in Middle-Aged and Older Athletes: Findings From the MARC-2 Study.
Aengevaeren, Vincent L. MD, PhD; Mosterd, Arend MD, PhD; Bakker, Esmee A. PhD; Braber, Thijs L. MD, PhD; Nathoe, Hendrik M. MD, PhD; Sharma, Sanjay MD; Thompson, Paul D. MD; Velthuis, Birgitta K. MD, PhD *,; Eijsvogels, Thijs M.H. PhD ,*
doi : 10.1161/CIRCULATIONAHA.122.061173
Physical activity and exercise training are associated with a lower risk for coronary events. However, cross-sectional studies in middle-aged and older male athletes revealed increased coronary artery calcification (CAC) and atherosclerotic plaques, which were related to the amount and intensity of lifelong exercise.
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
Gerstein, Hertzel C. MD, MSc; Li, Zhuoru MSc; Ramasundarahettige, Chinthanie MSc; Baek, Seungjae MD, PhD; Branch, Kelley R.H. MD, MSc; Del Prato, Stefano MD; Lam, Carolyn S.P. MBBS, PhD; Lopes, Renato D. MD, PhD; Pratley, Richard MD; Rosenstock, Julio MD; Sattar, Naveed FMedSci
doi : 10.1161/CIRCULATIONAHA.122.063716
In the AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes) cardiovascular outcomes trial, adding either 4 mg or 6 mg weekly of the glucagon-like peptide-1 receptor agonist efpeglenatide to usual care reduced major adverse cardiovascular events (MACE) in people with type 2 diabetes at high cardiovascular risk.
Pregnancy Complications and Long-Term Mortality in a Diverse Cohort.
Hinkle, Stefanie N. PhD; Schisterman, Enrique F. PhD; Liu, Danping PhD; Pollack, Anna Z. PhD, MPH; Yeung, Edwina H. PhD; Mumford, Sunni L. PhD; Grantz, Katherine L. MD, MS; Qiao, Yan MPH; Perkins, Neil J. PhD; Mills, James L. MD; Mendola, Pauline PhD; Zhang, Cuilin MD, PhD
doi : 10.1161/CIRCULATIONAHA.122.062177
Pregnancy complications are associated with increased risk of development of cardiometabolic diseases and earlier mortality. However, much of the previous research has been limited to White pregnant participants.
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling, Truman J. Jr MD ,*; Middeldorp, Saskia MD ,*; Xu, Lizhen PhD; Koch, Bruce PharmD; Demchuk, Andrew MD; Eikelboom, John W. MD; Verhamme, Peter MD; Cohen, Alexander T. MD; Beyer-Westendorf, Jan MD; Gibson, C. Michael MD; Lopez-Sendon, Jose MD; Crowther, Mark MD; Shoamanesh, Ashkan MD; Coppens, Michiel MD; Schmidt, Jeannot MD; Albaladejo, Pierre MD; Connolly, Stuart J. MD; on behalf of the ANNEXA-4 Investigators; Anand, R.; Bastani, A.; Clark, C.; Concha, M.; Cornell, J.; Dombrowski, K.; Fermann, G.; Fulmer, J.; Goldstein, J.; Kereiakes, D.; Milling, T.; Pallin, D.; Patel, N.; Refaai, M.; Rehman, M.; Schmaier, A.; Schwarz, E.; Shillinglaw, W.; Spohn, M.; Takata, T.; Venkat, A.; Welker, J.; Welsby, I.; Wilson, J.; Van Keer, L.; Verschuren, F.; Blostein, M.; Eikelboom, J.; Althaus, K.; Berrouschot, J.; Braun, G.; Doeppner, T.; Dziewas, R.; Genth-Zotz, S.; Greinacher, P.; Hamann, F.; Hanses, F.; Heide, W.; Kallmuenzer, B.; Kermer, P.; Poli, S.; Royl, G.; Schellong, S.; Schnupp, S.; Schwarze, J.; Spies, C.; Thomalla, G.; von Mering, M.; Weissenborn, K.; Wollenweber, F.; Gumbinger, C.; Jaschinski, U.; Maschke, M.; Mochmann, H-C.; Pfeilschifter, W.; Pohlmann, C.; Zahn, R.; Bouzat, P.; Schmidt, J.; Vallejo, C.; Floccard, B.; Coppens, M.; van Wissen, S.; Arellano-Rodrigo, E.; Valles, E.; Alikhan, R.; Breen, K.; Hall, R.; Crowther, M.; Albaladejo, P.; Cohen, A.; Demchuk, A.M.; Schmidt, J.; Wyse, D.G.; Garcia, D.A.; Prins, M.; Nakamya, J.; Buller, H.R.; Mahaffey, K. W.; Alexander, J. H.; Cairns, J.A.; Hart, R.G.; Joyner, C.D.; Raskob, G.E.; Schulman, S.; Veltkamp, R.; Meeks, B.; Zotova, E.; Ahmad, S.; Pinto, T.; Baker, K.; Dykstra, A.; Holadyk-Gris, I.; Malvaso, A.; Demchuk, A.M.
doi : 10.1161/CIRCULATIONAHA.121.057844
Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b/4, single-group cohort study that evaluated andexanet alfa in patients with acute major bleeding.
A Mouse Model of Atrial Fibrillation in Sepsis.
Bapat, Aneesh MD ,,*; Schloss, Maximilian J. MD ,,,*; Yamazoe, Masahiro MD, PhD; Grune, Jana PhD; Hulsmans, Maarten PhD; Milan, David J. MD; Nahrendorf, Matthias MD, PhD; Ellinor, Patrick T. MD, PhD
Letter by Shi et al Regarding Article, "Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy".
Shi, Rui MS; Fu, Feng MD, PhD; Ding, Mingge MD, PhD
Response by Dhingra et al to Letter Regarding Article, "Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy".
Dhingra, Rimpy PhD; Javaheri, Ali MD, PhD; Diwan, Abhinav MD; Kirshenbaum, Lorrie A. PhD
